ONCO: Onconetix, Inc. Stock

by  •  • Comments Off on ONCO: Onconetix, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 4.97
Enterprise Value ($M) 21.70
Book Value ($M) 41.02
Book Value / Share 4.95
Price / Book 0.12
NCAV ($M) -19.85
NCAV / Share -2.39
Price / NCAV -0.25

Profitability (mra)
Return on Invested Capital (ROIC) -1.01
Return on Assets (ROA) -0.59
Return on Equity (ROE) -36.74

Liquidity (mrq)
Quick Ratio 0.05
Current Ratio 0.06

Balance Sheet (mrq) ($M)
Current Assets 1.05
Assets 61.92
Liabilities 20.90
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G Zurcher Kantonalbank (Zurich Cantonalbank) 6.80
10-01 13D Bruhlmann Christian 5.23
10-01 13D Schiess Ralph 5.98
09-27 13G Scablis AG
09-26 13G New Horizon Health Ltd 6.91
09-26 13D Altos Venture AG 32.50 144.33
06-10 13G/A Hernandez Joseph 0.00 -100.00
2024-01-26 13G/A American Financial Group Inc 7.70 53.17

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-12-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-29 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-20 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-04-11 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 195,048 737,261 26.46
2025-02-03 124,328 535,713 23.21
2025-01-31 103,526 414,849 24.96
2025-01-30 174,606 694,440 25.14

(click for more detail)

Similar Companies
OCGN – Ocugen, Inc. OCX – OncoCyte Corporation
OKYO – OKYO Pharma Limited ONCY – Oncolytics Biotech Inc.
ONVO – Organovo Holdings, Inc.


Financial data and stock pages provided by
Fintel.io